Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024.
新澤西州普林斯頓，2023 年 12 月 13 日（GLOBE NEWSWIRE）——Acasti Pharma Inc.（納斯達克股票代碼：ACST）（Acasti 或該公司）是一家推進 GTX-104 的後期生物製藥公司，其新型尼莫地平靜脈注射配方正在開發中，以滿足一種罕見疾病，即動脈瘤性蛛網膜出血（aSaH）未得到滿足的醫療需求，今天宣佈，首席執行官普拉尚特·科利將在2024年1月7日至12日這一週參加在加利福尼亞州舊金山舉行的以下投資者和行業社交活動。
譯文內容由第三人軟體翻譯。